Table 1.
Respondent characteristics (N = 4,541)
| Mean (SD) | % Missing | |
|---|---|---|
| Age | 59.6 (12.6) | 9.9 |
| N | % | |
|---|---|---|
| Gender | ||
| Male | 2,511 | 55.3 |
| Female | 1,906 | 42.0 |
| Unknown | 124 | 2.7 |
| Stage | ||
| I–III | 1,846 | 40.7 |
| IV–recurrent/metastatic | 1,765 | 38.9 |
| Unknown | 930 | 20.5 |
| Site | ||
| Breast | 663 | 14.6 |
| Colorectal | 245 | 5.4 |
| Gynecological | 375 | 8.3 |
| Head and neck | 801 | 17.6 |
| Lung | 610 | 13.4 |
| Esophagus/stomach | 822 | 18.1 |
| Prostate | 405 | 8.9 |
| Other | 620 | 13.7 |
| Study type | ||
| RCT | 1,561 | 34.4 |
| Non-RCT | 1,455 | 32.0 |
| Field study | 1,386 | 30.5 |
| Unknown | 139 | 3.1 |
| Country | ||
| Belgium | 193 | 4.3 |
| Canada | 120 | 2.6 |
| France | 266 | 5.9 |
| Germany | 477 | 10.5 |
| Netherlands | 228 | 5.0 |
| Norway | 498 | 11.0 |
| Spain | 402 | 8.9 |
| Sri Lanka | 438 | 9.6 |
| Sweden | 202 | 4.4 |
| UK | 722 | 15.9 |
| USA | 157 | 3.5 |
| Other | 838 | 18.5 |